Navigation Links
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
Date:7/5/2011

AMSTERDAM, July 6, 2011 /PRNewswire/ --


 

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

"We are very fortunate to have attracted Carlos to AMT. He has joined the company at a pivotal point as we continue to pursue the approval our lead gene therapy Glybera with the EMA," stated Jörn Aldag, CEO of AMT. "His expertise in product development and related interaction with global regulatory bodies in the orphan drug field will prove invaluable, not only with Glybera, but also as we advance development of our gene therapy pipeline."

Dr. Camozzi will join AMT on July 18 from Orphan Europe, where he held the position of Medical Director for over 5 years. During his tenure, he oversaw the approval of Carbaglu, a product for hyperammonemia in NAGS deficiency and Organic Acidemias, with the EMA and FDA, EMEA marketing authorisation renewals for two products, three orphan drug designations and development of pediatric investigation plans. He was also responsible for the clinical development in the pediatric field of orphan drugs in therapeutic areas of metabolic disorders, immunology, dermatology, cardiology and CNS.

Prior to Orphan Europe, Dr. Camozzi was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Basel, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities. From 2001-2005, he was managing director of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programs for pharmaceutical and healthcare products.
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
2. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
9. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
10. NIH grant ratchets up ASU research in molecular motors
11. SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
(Date:1/22/2015)... Jan. 22, 2015   GenoSpace , a precision medicine software ... enable the broad use of genomic, imaging and other biomedical ... of Michelle Munson , CEO of Aspera, an IBM ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We are ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Approved in Atlanta ATLANTA, May 19 Meeting ... the Kansas Bioscience Authority has approved more than ... a $581 million initiative to help researchers and ... at the Bio International Convention will create bioscience ...
... availability of the world,s first clinical guidelines to allow U.S. doctors ... disease. , ... Broomfield, CO (PRWEB) May 19, 2009 ... today the availability of the world,s first clinical guidelines to allow ...
... illustrate potential cost effective approach for, ... Symbol: RVX,CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - ... pleased to announce today that it has made ... (R&D) program for inflammatory diseases. Two new patent ...
Cached Biology Technology:As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 2As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 3As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 4Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 2Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 3Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 4Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 2Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 3
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... of cancer cells can be switched on using drugs, ... Center. The finding could lead to a new class ... different cancer types. , Popular new drugs such as ... genetic mutations that express themselves in large amounts, causing ...
... the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian ... antibodies in human blood that may help to ... as other neurodegenerative diseases. , The newly ... proteins called "oligomers" that are toxic to brain ...
... the protein complex implicated in autism spectrum disorders, a ... California, San Diego (UCSD) Skaggs School of Pharmacy and ... this complex and contribute to the developmental abnormalities found ... cover article in the June issue of the journal ...
Cached Biology News:U-M researchers discover gene switched off in cancer can be turned on 2U-M researchers discover gene switched off in cancer can be turned on 3Newly discovered antibody may be body's natural defense against Alzheimer's 2Newly discovered antibody may be body's natural defense against Alzheimer's 3Researchers reveal structure of protein altered in autism 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: